Solid Tumors and Hematologic Malignancy Clinical Trial
Official title:
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (mono therapy dose escalation) will determine the recommended dose(s) of INCB059872 for dose expansion, based on maximum tolerated dose and/or a tolerated pharmacologically active dose. Part 2 (dose expansion) will further determine the safety, tolerability, efficacy, PK, and PD of the selected monotherapy dose(s) in AML/MDS, SCLC, myelofibrosis, Ewing sarcoma, and poorly differentiated neuroendocrine tumors. Part 3 will determine the recommended dose(s) of INCB059872 in combination with azacitadine and all-trans retinoic acid in AML and in combination with nivolumab in SCLC. Part 4 will further determine the safety, tolerability, efficacy, PK, and PD of the selected combination dose(s) in Part 3.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02492789 -
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
|
Phase 1 | |
| Completed |
NCT01195311 -
A Dose-escalation Study in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00820560 -
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02355431 -
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
|
Phase 2 | |
| Terminated |
NCT02431260 -
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
|
Phase 1/Phase 2 |